RESUMEN
A cardiomiopatia hipertrófica é uma doença genética com apresentação, prognóstico e estratégias de tratamento variáveis. A visibilidade ligada à cardiomiopatia hipertrófica refere-se em grande parte a seu reconhecimento como causa comum de taquiarritmias e morte súbita cardíaca. O cardiodesfibrilador implantável é aceito como tratamento definitivo para prevenção de morte súbita, especialmente em pacientes de alto risco. Apesar da baixa prevalência, a via acessória é encontrada em 5% dos pacientes com cardiomiopatia hipertrófica e a ablação é o método de escolha, em decorrência do risco de taquiarritmias atriais. Relatamos o caso de um paciente com cardiomiopatia hipertrófica, em fase dilatada, com via acessória.
Hypertrophic cardiomyopathy is a genetic disease with variable presentation, prognosis and treatment strategies. The visibility linked to hypertrophic cardiomyopathy to a large extent refers to its recognition as a common cause of tachyarrhythmias and sudden cardiac death. Implantable cardiac defibrillator is accepted as definitive treatment for the prevention of sudden death, especially in high-risk patients. Despite the low prevalence, the accessory pathway is found in 5% of patients with hypertrophic cardiomyopathy and ablation is the method of choice due to risk of atrial tachyarrhythmias. We report the case of a patient with dilated hypertrophic cardiomyopathy and an accessory pathway.
Asunto(s)
Humanos , Masculino , Adulto , Síndrome de Wolff-Parkinson-White , Cardiomiopatía Hipertrófica/diagnóstico , Cardiomiopatía Hipertrófica/terapia , Cardiomiopatía Dilatada/diagnóstico , Cardiomiopatía Dilatada/terapia , Volumen Sistólico , Muerte Súbita Cardíaca , Desfibriladores Implantables/tendencias , Ablación por Catéter/métodosRESUMEN
A amiloidose cardíaca é uma doença caracterizada pelo depósito de proteínas amiloides no tecido cardíaco. É uma doença subdiagnosticada ou diagnosticada já em fases muito avançadas, já que os métodos usualmente utilizados como o eletrocardiograma e o ecocardiograma transtorácico apresentam baixa sensibilidade nas fases iniciais da doença. O padrão ouro no diagnóstico dessa patologia é a biópsia endomiocárdica (BEM)...
Asunto(s)
Amiloidosis , Imagen por Resonancia Magnética , Insuficiencia CardíacaRESUMEN
We investigated the adsorption capacity and photocatalytic removal efficiency of formaldehyde using a hectorite-TiO(2) composite in a bench flow reactor. The same experimental conditions were applied to pure TiO(2) (Degussa P25) as a reference. The catalysts were irradiated with either a UVA lamp (365 nm) or with one of two UVC lamps of 254 nm and 254+185 nm, respectively. Formaldehyde was introduced upstream at concentrations of 100-500 ppb, with relative humidity (RH) in the range 0-66% and residence times between 50 and 500 ms. Under dry air and without illumination, saturation of catalyst surfaces was achieved after ≈ 200 min for P25 and ≈ 1000 min for hectorite-TiO(2). The formaldehyde uptake capacity by hectorite-TiO(2) was 4.1 times higher than that of P25, almost twice the BET surface area ratio. In the presence of humidity, the difference in uptake efficiency between both materials disappeared, and saturation was achieved faster (after ≈ 200 min at 10% RH and ≈ 60 min at 65% RH). Under irradiation with each of the three UV sources, removal efficiencies were proportional to the Ti content and increased with contact time. The removal efficiency decreased at high RH. A more complete elimination of formaldehyde was observed with the 254+185 nm UV source.